Design of a small-molecule entry inhibitor with activity against primary measles virus strains

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Measles virus (MV) infection remains a global health concern, causing significant morbidity and mortality, particularly in developing nations.
• Outbreaks persist in developed countries with suboptimal vaccine coverage, highlighting the need for effective case management beyond vaccination.
• Current therapeutic options for measles are limited, emphasizing the demand for novel antiviral agents to reduce disease severity.

Purpose of the Study:

• To develop small-molecule inhibitors of measles virus entry with enhanced stability and potent antiviral activity.
• To address the limitations of initial lead compounds, specifically their short half-life under physiological conditions.
• To identify a novel therapeutic agent for measles that complements vaccination strategies.

Main Methods:

• Synthesis and testing of a targeted library of small-molecule MV entry inhibitors based on a structural scaffold.
• Evaluation of compound stability, toxicity, and antiviral efficacy against a panel of wild-type MV strains.
• Determination of 50% inhibitory concentrations (IC50) across different MV genotypes.

Main Results:

• An improved lead compound was identified with low toxicity and significantly enhanced stability (half-life >> 16 hours).
• This compound effectively prevents measles virus entry and subsequent infection.
• High MV specificity and potent antiviral activity were demonstrated, with IC50 values ranging from 0.6 to 3.0 microM depending on the MV genotype.

Conclusions:

• A novel, stable, and potent small-molecule inhibitor of measles virus entry has been developed.
• This compound represents a promising therapeutic candidate for managing measles infection, offering an alternative or adjunct to vaccination.
• Further development of this agent could significantly impact global measles morbidity and mortality.